作者: Thierry Hennet , Emma Salomonsson , Bruce Mcconnell , Louise Kristine Vigsnæs
DOI:
关键词:
摘要: The application relates to synthetic compositions containing one or more human milk mono- oligosaccharides for use treating irritable bowel syndrome and symptoms relating syndrome. HMS is preferably selected from sialic acid fucose the HMO 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose (LNFP-I) 3',6-disialyllacto-N- tetraose (DSLNT).